Published in Vaccine Weekly, August 14th, 1995
It has been well documented in the human and in the primate that trachoma results primarily from an immunopathologic response to repeated or chronic infection with Chlamydia trachomatis.
Although the use of a whole elementary body vaccine for trachoma is not endorse, it is of interest to determine those chlamydial components responsible for eliciting the pathologic response. By definition, these may not be the optimal components of a vaccine and should be deleted from a potential vaccine.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.